Repeated relapses of acute myelogenous leukemia in the isolated extramedullary sites following allogeneic bone marrow transplantations

Yoshikane Kikushige, Ken Takase, Keiko Sata, Ken Ichi Aoki, Akihiko Numata, Toshihiro Miyamoto, Takahiro Fukuda, Hisashi Gondo, Mine Harada, Koji Nagafuji

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Isolated extramedullary (EM) relapses of acute myelogenous leukemia (AML) after allogeneic hematopoietic stem cell transplantation (allo-HSCT) have been reported to be rare, and are usually followed by bone marrow relapses. We report a 49-year-old man with AML with the unfavorable chromosome abnormality 7q-, who was treated by allo-HSCT. Fifteen months after allo-HSCT, the patient initially developed a relapse only in his inguinal lymph nodes, and then bone marrow relapse became evident one month after the EM relapse. Subsequently, the patient received chemotherapy and a second allo-HSCT from another donor, but he suffered another relapse in different EM sites including the skin and central nervous system with a persistently normal marrow. This case is characterized by repeated relapses in isolated EM sites after allo-HSCT and suggests that the anti-leukemic effects of chemotherapy and/or graft-versus-leukemia effects in the EM sites might not be so uniformly effective as that in the marrow. Accordingly, we should be aware that AML relapses can occur repeatedly only in isolated EM sites post allo-HSCT, resulting in treatment failure and a poor prognosis.

Original languageEnglish
Pages (from-to)1011-1014
Number of pages4
JournalInternal Medicine
Volume46
Issue number13
DOIs
Publication statusPublished - Jul 2 2007

Fingerprint

Homologous Transplantation
Bone Marrow Transplantation
Acute Myeloid Leukemia
Hematopoietic Stem Cell Transplantation
Recurrence
Bone Marrow
Drug Therapy
Groin
Treatment Failure
Chromosome Aberrations
Leukemia
Central Nervous System
Lymph Nodes
Tissue Donors
Transplants
Skin

All Science Journal Classification (ASJC) codes

  • Internal Medicine

Cite this

Repeated relapses of acute myelogenous leukemia in the isolated extramedullary sites following allogeneic bone marrow transplantations. / Kikushige, Yoshikane; Takase, Ken; Sata, Keiko; Aoki, Ken Ichi; Numata, Akihiko; Miyamoto, Toshihiro; Fukuda, Takahiro; Gondo, Hisashi; Harada, Mine; Nagafuji, Koji.

In: Internal Medicine, Vol. 46, No. 13, 02.07.2007, p. 1011-1014.

Research output: Contribution to journalArticle

Kikushige, Yoshikane ; Takase, Ken ; Sata, Keiko ; Aoki, Ken Ichi ; Numata, Akihiko ; Miyamoto, Toshihiro ; Fukuda, Takahiro ; Gondo, Hisashi ; Harada, Mine ; Nagafuji, Koji. / Repeated relapses of acute myelogenous leukemia in the isolated extramedullary sites following allogeneic bone marrow transplantations. In: Internal Medicine. 2007 ; Vol. 46, No. 13. pp. 1011-1014.
@article{6dd8955343b64c62be9dbf5609a75a3c,
title = "Repeated relapses of acute myelogenous leukemia in the isolated extramedullary sites following allogeneic bone marrow transplantations",
abstract = "Isolated extramedullary (EM) relapses of acute myelogenous leukemia (AML) after allogeneic hematopoietic stem cell transplantation (allo-HSCT) have been reported to be rare, and are usually followed by bone marrow relapses. We report a 49-year-old man with AML with the unfavorable chromosome abnormality 7q-, who was treated by allo-HSCT. Fifteen months after allo-HSCT, the patient initially developed a relapse only in his inguinal lymph nodes, and then bone marrow relapse became evident one month after the EM relapse. Subsequently, the patient received chemotherapy and a second allo-HSCT from another donor, but he suffered another relapse in different EM sites including the skin and central nervous system with a persistently normal marrow. This case is characterized by repeated relapses in isolated EM sites after allo-HSCT and suggests that the anti-leukemic effects of chemotherapy and/or graft-versus-leukemia effects in the EM sites might not be so uniformly effective as that in the marrow. Accordingly, we should be aware that AML relapses can occur repeatedly only in isolated EM sites post allo-HSCT, resulting in treatment failure and a poor prognosis.",
author = "Yoshikane Kikushige and Ken Takase and Keiko Sata and Aoki, {Ken Ichi} and Akihiko Numata and Toshihiro Miyamoto and Takahiro Fukuda and Hisashi Gondo and Mine Harada and Koji Nagafuji",
year = "2007",
month = "7",
day = "2",
doi = "10.2169/internalmedicine.46.6384",
language = "English",
volume = "46",
pages = "1011--1014",
journal = "Internal Medicine",
issn = "0918-2918",
publisher = "Japanese Society of Internal Medicine",
number = "13",

}

TY - JOUR

T1 - Repeated relapses of acute myelogenous leukemia in the isolated extramedullary sites following allogeneic bone marrow transplantations

AU - Kikushige, Yoshikane

AU - Takase, Ken

AU - Sata, Keiko

AU - Aoki, Ken Ichi

AU - Numata, Akihiko

AU - Miyamoto, Toshihiro

AU - Fukuda, Takahiro

AU - Gondo, Hisashi

AU - Harada, Mine

AU - Nagafuji, Koji

PY - 2007/7/2

Y1 - 2007/7/2

N2 - Isolated extramedullary (EM) relapses of acute myelogenous leukemia (AML) after allogeneic hematopoietic stem cell transplantation (allo-HSCT) have been reported to be rare, and are usually followed by bone marrow relapses. We report a 49-year-old man with AML with the unfavorable chromosome abnormality 7q-, who was treated by allo-HSCT. Fifteen months after allo-HSCT, the patient initially developed a relapse only in his inguinal lymph nodes, and then bone marrow relapse became evident one month after the EM relapse. Subsequently, the patient received chemotherapy and a second allo-HSCT from another donor, but he suffered another relapse in different EM sites including the skin and central nervous system with a persistently normal marrow. This case is characterized by repeated relapses in isolated EM sites after allo-HSCT and suggests that the anti-leukemic effects of chemotherapy and/or graft-versus-leukemia effects in the EM sites might not be so uniformly effective as that in the marrow. Accordingly, we should be aware that AML relapses can occur repeatedly only in isolated EM sites post allo-HSCT, resulting in treatment failure and a poor prognosis.

AB - Isolated extramedullary (EM) relapses of acute myelogenous leukemia (AML) after allogeneic hematopoietic stem cell transplantation (allo-HSCT) have been reported to be rare, and are usually followed by bone marrow relapses. We report a 49-year-old man with AML with the unfavorable chromosome abnormality 7q-, who was treated by allo-HSCT. Fifteen months after allo-HSCT, the patient initially developed a relapse only in his inguinal lymph nodes, and then bone marrow relapse became evident one month after the EM relapse. Subsequently, the patient received chemotherapy and a second allo-HSCT from another donor, but he suffered another relapse in different EM sites including the skin and central nervous system with a persistently normal marrow. This case is characterized by repeated relapses in isolated EM sites after allo-HSCT and suggests that the anti-leukemic effects of chemotherapy and/or graft-versus-leukemia effects in the EM sites might not be so uniformly effective as that in the marrow. Accordingly, we should be aware that AML relapses can occur repeatedly only in isolated EM sites post allo-HSCT, resulting in treatment failure and a poor prognosis.

UR - http://www.scopus.com/inward/record.url?scp=34547890658&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34547890658&partnerID=8YFLogxK

U2 - 10.2169/internalmedicine.46.6384

DO - 10.2169/internalmedicine.46.6384

M3 - Article

C2 - 17603242

AN - SCOPUS:34547890658

VL - 46

SP - 1011

EP - 1014

JO - Internal Medicine

JF - Internal Medicine

SN - 0918-2918

IS - 13

ER -